title: Heparin calcium treated Henoch-Schönlein purpura nephritis in children through inhibiting hyperfibrinolysis.
abstract: OBJECTIVE
  To explore the underlying mechanism of low-molecular-weight heparin calcium therapy on Henoch-Schönlein purpura nephritis (HSPN).
  
  
  METHODS
  Eighty-nine children with severe HSPN were randomized into control group (treated with conventional therapy, n = 45) and treatment group (treated with conventional therapy plus low-molecular-weight heparin calcium, n = 44). The concentrations of plasma fibrinogen (Fg), d-dimer and fibrin degradation products (FDPs) were detected before and after treatment. The urinary red blood cell (RBC) and 24 h proteinuria were determined weekly for assessing the children's kidney function.
  
  
  RESULTS
  Two groups were well-matched at baseline. After 8 weeks of treatment, the clinical outcomes of HSPN and outcome of proteinuria of the treatment group were better than the control group (p < 0.05); the content of Fg, d-dimer and FDP in plasma of the treatment group were lower than the control group (p < 0.05); but there was no difference about the curative effect of hematuria and the coagulation function between the two groups (p > 0.05).
  
  
  CONCLUSIONS
  Fibrinolytic system may participate in the kidney injury of HSPN children and low-molecular-weight heparin calcium could correct blood hypercoagulability through inhibiting hyperfibrinolysis, and thus improving the blood supply of kidney.
authors.affiliation: a Department of Kidney Rheumatology , Children's Hospital of Zhengzhou , Zhengzhou City , Henan Province , China.
authors.forename: Ming
authors.initials: M
authors.lastname: Tian
authors.affiliation: a Department of Kidney Rheumatology , Children's Hospital of Zhengzhou , Zhengzhou City , Henan Province , China.
authors.forename: Cuihua
authors.initials: C
authors.lastname: Liu
mesh_terms: D001777:Blood Coagulation; D002648:Child; D002675:Child, Preschool; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications*; D007668:Kidney / Q000098:blood supply*; D008297:Male; D009393:Nephritis / Q000188:drug therapy*; D011507:Proteinuria / Q000652:urine*; D016896:Treatment Outcome
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; C036309:fibrin fragment D; C006871:calcium heparin; D006493:Heparin
keywords: Fibrinolytic system; Henoch–Schönlein purpura nephritis (HSPN); low-molecular-weight heparin calcium